LB Pharmaceuticals’ (LBRX) Buy Rating Reiterated at HC Wainwright

by · The Markets Daily

HC Wainwright restated their buy rating on shares of LB Pharmaceuticals (NASDAQ:LBRX – Free Report) in a research note published on Monday morning,Benzinga reports. The brokerage currently has a $45.00 price objective on the stock. HC Wainwright also issued estimates for LB Pharmaceuticals’ Q3 2026 earnings at ($0.95) EPS, Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($3.51) EPS, Q1 2027 earnings at ($1.13) EPS, Q2 2027 earnings at ($1.19) EPS, Q3 2027 earnings at ($1.26) EPS, Q4 2027 earnings at ($1.29) EPS and FY2027 earnings at ($4.87) EPS.

LBRX has been the subject of several other research reports. Weiss Ratings upgraded shares of LB Pharmaceuticals from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Friday, July 24th. BMO Capital Markets began coverage on shares of LB Pharmaceuticals in a research report on Monday, July 20th. They issued an “outperform” rating and a $46.00 target price on the stock. Wolfe Research started coverage on shares of LB Pharmaceuticals in a research note on Tuesday, July 7th. They set an “outperform” rating and a $45.00 price target on the stock. Roth Capital reissued a “buy” rating and issued a $37.00 price target on shares of LB Pharmaceuticals in a research report on Sunday, May 17th. Finally, Craig Hallum began coverage on LB Pharmaceuticals in a report on Friday, April 10th. They set a “buy” rating and a $36.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.12.

View Our Latest Report on LB Pharmaceuticals

LB Pharmaceuticals Stock Performance

Shares of NASDAQ LBRX opened at $45.03 on Monday. LB Pharmaceuticals has a fifty-two week low of $13.36 and a fifty-two week high of $46.01. The firm has a market capitalization of $1.29 billion and a PE ratio of -26.03. The stock’s 50-day simple moving average is $32.44 and its 200-day simple moving average is $28.21.

LB Pharmaceuticals (NASDAQ:LBRX – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, sell-side analysts forecast that LB Pharmaceuticals will post -3.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On LB Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Spruce Street Capital LP purchased a new stake in shares of LB Pharmaceuticals in the fourth quarter valued at about $22,384,000. Jennison Associates LLC boosted its stake in shares of LB Pharmaceuticals by 11.2% during the fourth quarter. Jennison Associates LLC now owns 821,852 shares of the company’s stock worth $18,294,000 after buying an additional 82,812 shares during the period. Stempoint Capital LP purchased a new position in shares of LB Pharmaceuticals during the first quarter worth about $1,233,000. Eversept Partners LP acquired a new position in LB Pharmaceuticals in the 1st quarter valued at about $2,471,000. Finally, Calamos Advisors LLC purchased a new stake in LB Pharmaceuticals during the 1st quarter valued at approximately $593,000.

LB Pharmaceuticals News Summary

Here are the key news stories impacting LB Pharmaceuticals this week:

  • Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $3.51 from $3.61 and its FY2027 estimate to a loss of $4.87 from $5.30. Quarterly estimates were also improved, including Q3 2026 to a loss of $0.95, Q4 2026 to $1.07, and each quarter of 2027. The revisions indicate better anticipated earnings performance, although LB Pharmaceuticals is still expected to remain unprofitable. HC Wainwright Reaffirms Buy Rating for LB Pharmaceuticals
  • Neutral Sentiment: The $45 price target is broadly in line with the stock’s recent trading level, limiting the immediate implied upside from HC Wainwright’s recommendation. The company also continues to carry a negative earnings outlook, with consensus calling for a full-year loss of $3.58 per share.

About LB Pharmaceuticals

(Get Free Report)

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.

Further Reading